Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes. The company's gross revenue in 2018 was $782.4 million; gross income was $438.2 million; earnings before interest, taxes, depreciation, and amortization were $170.5 million.
Among the company's notable products are BioThrax, the only anthrax vaccine licensed by the U.S. Food and Drug Administration and Narcan for the emergency treatment of opioid overdose. The company also manufactures pharmaceuticals for infectious diseases like cholera and typhoid.
Fuad El-Hibri, the founder of the company and former CEO, led the company since its founding as BioPort Inc. until his retirement on April 1, 2012. El-Hibri continues to serve as the executive chairman of Emergent BioSolutions’ board of directors.
Highest paying job titles at Emergent BioSolutions include Quality Assurance Engineer, Quality Assurance Manager, and Senior Scientist